Drug Trial Radar · NCT06188702
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
61
Actual
Start
Apr 29, 2024
Primary completion
May 1, 2027
Study completion May 1, 2027
Sponsor
- Lead sponsor
- Servier Bio-Innovation LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Institut de Recherches Internationales Servier; Tango Therapeutics, Inc.
- First posted
- Jan 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \[MAT2A\] inhibitor. TNG462 is a protein arginine N-methyltransferase 5 \[PRMT5\] inhibitor.
Conditions
- MTAP-deleted Solid Tumors
Interventions
S095035Drug
S095035 will be taken orally every day in 28-day cycles.
TNG462Drug
TNG462 will be taken orally every day in 28-day cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicities (DLTs)Time frame: Through cycle 1 (each cycle is 28 days)
- Total number of adverse events (AEs)Time frame: Through the Safety Follow-up Visit (until 30 days after the last dose of study treatment) approximately 5 years
- Total number of serious adverse events (SAEs)Time frame: Through the Safety Follow-up Visit (until 30 days after the last dose of study treatment) approximately 5 years
- Objective response rate (ORR)Time frame: Through the end of the study (approximately 5 years)
Locations
20 sites in 7 countries. Site status is shown where the registry gives one.
Lake Mary Cancer Center - Florida Cancer Specialists & Research Institute
Lake Mary, Florida
Community Health Network
Indianapolis, Indiana
Taylor Cancer Research Center
Maumee, Ohio
SCRI Oncology Partners
Nashville, Tennessee
NEXT Oncology
Austin, Texas
Townsville University Hospital
Douglas, Australia
Royal Hobart Hospital
Hobart, Australia
Scientia Clinical Research
Randwick, New South Wales, Australia
The Alfred
Prahran, Victoria, Australia
Institut Bergonié
Bordeaux, France
Centre Georges-François Leclerc
Dijon, France
Universitätsklinikum Ulm
Ulm, Germany
Istituto Europeo Di Oncologia
Milan, Italy
Instituto Clinico Humanitas Irccs
Rozzano, Italy
Policlinico G.B. Rossi A.O.U.I. Di Verona
Verona, Italy
Aichi Cancer Center
Aichi, Japan
National Hospital Organization Shikoku Cancer Center
Ehime, Japan
The Cancer Institute Hospital of JFCR
Tokyo, Japan
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Start Madrid Group - Hm Ciocc
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.